- TRADE NAMES: Melanotan (Clinuvel); Scenesse (Clinuvel)
- INDICATIONS: Erythropoetic protoporphyria, polymorphous light eruption, photodamage
- CLASS: Melanocortin receptor agonist, Melanocyte stimulating hormone A agonist, Photoprotective
- HALF-LIFE: ~15 hr when administered subcutaneously in a controlled release implant.
- FDA APPROVAL DATE: 10/08/2019 (as an implant)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no data in pregnant women to evaluate for any drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
